4 Pharma stocks with high dividend yield to add to your watchlist4 Pharma stocks with high dividend yield to add to your watchlist

Introduction

Dividend yield in the stock market shows how much a company pays in dividends each year compared to its share price. It is a useful measure for understanding income from holding a stock.

In the pharma sector, some companies not only grow steadily but also give high dividends. These payouts reward shareholders regularly. Here are four pharmaceutical stocks known for offering attractive dividend yields along with consistent business performance.

Also Read: Textile stock in focus after company announces ₹150 dividend and strong Q1 results

Novartis India

On August 8, 2025, Novartis India Ltd opened at ₹935.25, up 0.05% from its previous close of ₹934.80. The stock reached a high of ₹955.00 and a low of ₹915.90. By 4:00 PM, it traded at ₹921.75, a 1.40% decline, with a market cap of ₹2,275.87 crore.

Novartis India Ltd offers a high dividend yield of 2.67% and maintains a low debt-to-equity ratio of 0.01.

Novartis India Ltd (NSE: NOVARTIND) operates in the pharmaceutical sector, focusing on pain management, organ transplantation, and neuroscience, importing a range of medicines from global sources for distribution in the Indian market.

Alivus Life Sciences

On August 8, 2025, Alivus Life Sciences Ltd opened at ₹930.90, down 0.05% from its previous close of ₹935.80. The stock reached a high of ₹939.20 and a low of ₹925.80. By 4:00 PM, it traded at ₹931.75, a 0.43% decline, with a market cap of ₹11,425.97 crore.

Alivus Life Sciences Ltd delivers a high dividend yield of 2.43% and maintains a low debt-to-equity ratio of 0.02.

Alivus Life Sciences Ltd (NSE: ALIVUS), a Nirma Limited subsidiary, develops and manufactures high-value APIs in chronic therapeutic areas and offers contract development and manufacturing services to specialty pharmaceutical companies globally.

Also Read: Auto ancillary stock hits 10% lower circuit after its net profits fall 29.9% QoQ

Sanofi India

On August 8, 2025, Sanofi India Ltd opened at ₹5,191.25, up 0.12% from its previous close of ₹5,185.15. The stock reached a high of ₹5,239.00 and a low of ₹5,161.00. By 4:00 PM, it traded at ₹5,205.55, a 0.39% increase, with a market cap of ₹11,988.38 crore.

Sanofi India Ltd offers a high dividend yield of 2.27% and maintains a low debt-to-equity ratio of 0.03.

Sanofi India Ltd (NSE: SANOFI) is a leading multinational in the Indian pharmaceutical market, offering medicines for diabetes, cardiology, thrombosis, CNS disorders, and anti-histamine treatments across diverse therapeutic areas.

Procter & Gamble

On August 8, 2025, Procter & Gamble Health Ltd opened at ₹6,313.00, up 0.07% from its previous close of ₹6,308.55. The stock reached a high of ₹6,356.50 and a low of ₹6,222.60. By 4:00 PM, it traded at ₹6,334.10, a 0.41% increase, with a market cap of ₹10,514.21 crore.

Procter & Gamble Health Ltd provides a high dividend yield of 1.97% and holds a low debt-to-equity ratio of 0.01.

Procter & Gamble Health Ltd (NSE: PGHL), formerly Merck Limited, manufactures and markets pharmaceuticals and chemicals, specializing in vitamins, minerals, and supplements, with well-known brands like Evion, Neurobion, Nasivion, Polybion, and Livogen in its portfolio.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Which pharma companies offer high dividend yields and low debt?

A: Novartis India, Alivus Life Sciences, Sanofi India, and Procter & Gamble Health offer attractive yields with low debt ratios.

Q: What does high dividend yield mean in the stock market?

A: High dividend yield shows a company’s annual dividend compared to its share price, indicating strong shareholder payouts.

Q: Why are high-dividend pharma stocks appealing?

A: They combine steady earnings, regular shareholder rewards, and financial stability, making them attractive for income-focused market participants.